Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
In: Osteoporosis International, Jg. 28 (2017), Heft 1, S. 389-398
Online
academicJournal
Zugriff:
Summary: In a 2-year randomized, placebo-controlled study of 665 Japanese patients with primary osteoporosis, once-yearly administration of zoledronic acid (5 mg) reduced the risk of new morphometric vertebral fractures. Introduction: The purpose of this study was to determine the efficacy and safety of once-yearly intravenous infusion of ZOL in Japanese patients with primary osteoporosis. Methods: This was a two-year multicenter, randomized, placebo-controlled, double-blind, parallel-group comparative study (ZONE Study). Subjects were 665 Japanese patients between the ages of 65 and 89 years who had prevalent vertebral fracture. Subjects were randomly assigned to receive once-yearly intravenous infusion of 5 mg of ZOL or placebo at baseline and 12 months. Results: The 2-year incidence of new morphometric vertebral fracture was 3.0 % (10/330 subjects) in the ZOL group and 8.9 % (29/327) in the placebo group ( p = 0.0016). The 24-month cumulative incidence of new morphometric vertebral fracture was 3.3 % in the ZOL group versus 9.7 % in the placebo group (log-rank test: p = 0.0029; hazard ratio: 0.35; 95 % confidence interval: 0.17-0.72). The cumulative incidence of any clinical fracture, clinical vertebral fracture, and non-vertebral fracture was significantly reduced in the ZOL group by 54, 70, and 45 %, respectively, compared to the placebo group. At 24 months, ZOL administration increased bone mineral density in the lumbar spine, femoral neck, and total hip ( t test: p < 0.0001). No new adverse events or osteonecrosis of the jaw were observed in this study. Conclusions: Once-yearly administration of ZOL 5 mg to Japanese patients with primary osteoporosis reduced the risk of new morphometric vertebral fractures and was found to be safe. [ABSTRACT FROM AUTHOR]
Copyright of Osteoporosis International is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
|
---|---|
Autor/in / Beteiligte Person: | Nakamura, T. ; Fukunaga, M. ; Nakano, T. ; Kishimoto, H. ; Ito, M. ; Hagino, H. ; Sone, T. ; Taguchi, A. ; Tanaka, S. ; Ohashi, M. ; Ota, Y. ; Shiraki, M. |
Link: | |
Zeitschrift: | Osteoporosis International, Jg. 28 (2017), Heft 1, S. 389-398 |
Veröffentlichung: | 2017 |
Medientyp: | academicJournal |
ISSN: | 0937-941X (print) |
DOI: | 10.1007/s00198-016-3736-y |
Schlagwort: |
|
Sonstiges: |
|